share_log

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target

HC Wainwright & Co.重申買入Capricor Therapeutics,維持40美元的目標股價
Benzinga ·  04/25 07:25

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40 price target.

HC Wainwright & Co. 分析師約瑟夫·潘吉尼斯重申Capricor Therapeutics(納斯達克股票代碼:CAPR)的買入並維持40美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論